Isodiol International Inc ISOLF

RE:So much noise and

[jb24]

Well said Barstool. gltals

BarstoolSage wrote:

no mention of Compass backing (seems to have been from their side) out of the Canadian dispensary deal whereby ISOL was to buy 19.9% of Compass and gain exclusive distribution in Canada for their CBDs. Maybe Compass had second thoughts about the exclusivity???We'll never know exactly why


But I liked it when it happened, and like it less now that it has been cancelled.  Do understand ISOL probably still has non exclusive rights, but I like the idea of getting a Canadian dispensary or pharmacy...and dreaming out loud, Shoppers Loblaws would be an absolute major score. PC products with CBDs?


OK. No Compass, and dreaming out loud over, what we still have is a huge source of hemp, state of the art, high throughput extraction equipment and methods, proprietary formulae and delivery mechanisms, some highly capable, successful and reputable scientists, great relationship with key groups like Serruyas for financing and Kathy Ireland on the marketing side, and management focus on geographical expansion of markets and operations.


December 31 2017 financials showed $26 million in cash and $50 million in shareholders equity, no debt and the upcoming 18 million financing looks to fund the company's recent expansion announcements. Revenues for the nine months to December 31 were just over 13.5 million, meaning 6.5 million more to break 20 this year...not calling that it will\has ==March 31 2018 is past===, but nice if it has.


As this is summarizing, it bears repeating the financials show no ownership pf an Indian subsidiary, so ImmunAG and its strain of hops is not owned by ISOL, but comes to ISOL vs some kind of relationship with its owners. ISOL seems to have a non exclusive right to sell ImmunAG, and can presumably use its proprietary IP to process those hops.  
 

I began accumulating ISOL last year around this time, and it is nowhere near the company it was back then. It had a great run and spike late November early December 2018, as it ran with the rest of the market frenzy, but is still up 3 to fourfold for me in the year, AND the future will pay off with ISOL.
 

Wholesale and retail sales will both grow as more and more attention is paid to CBDs and the science around it is developed, by ISOL and the market in general.  


Among all the noise from bashers and pumpers, this all still makes a lot of sense to me.
 

A year out, I am still all in and more importantly, all in to a profoundly different company that has demonstrated it knows what it is doing and needs to do in order to capitalize on the coming CBD and phytoceutical market growth.